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Bacillus Calmette Guérin (BCG) is the only currently available vaccine against tuberculosis
(TB), but it confers incomplete and variable protection against pulmonary TB in
humans and bovine TB (bTB) in cattle. Insights into the immune response induced
by BCG offer an underexploited opportunity to gain knowledge that may inform the
design of a more efficacious vaccine, which is urgently needed to control these major
global epidemics. Humoral immunity in TB and bTB has been neglected, but recent
studies supporting a role for antibodies in protection against TB has driven a growing
interest in determining their relevance to vaccine development. In this manuscript we
review what is known about the humoral immune response to BCG vaccination and
re-vaccination across species, including evidence for the induction of specific B cells
and antibodies; and how these may relate to protection from TB or bTB. We discuss
potential explanations for often conflicting findings and consider how factors such
as BCG strain, manufacturing methodology and route of administration influence the
humoral response. As novel vaccination strategies include BCG prime-boost regimens,
the literature regarding off-target immunomodulatory effects of BCG vaccination on
non-specific humoral immunity is also reviewed. Overall, reported outcomes to date
are inconsistent, but indicate that humoral responses are heterogeneous and may play
different roles in different species, populations, or individual hosts. Further study is
warranted to determine whether a new TB vaccine could benefit from the targeting of
humoral as well as cell-mediated immunity.
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INTRODUCTION
Tuberculosis (TB), caused byMycobacterium tuberculosis (M.tb), continues to pose a major global
health threat with 10million new cases and 1.6million deaths per year (1). Bovine TB (bTB), caused
mainly by the related Mycobacterium bovis (M.bovis), is one of the principal diseases reducing
livestock production and thus wealth in Africa, South Asia and South America, with an estimated
global annual impact of US $3 billion (2, 3). bTB also has public health implications, and in 2017
theWorld Health Organization (WHO), Food and Agriculture Organization of the United Nations
(FAO), World Organization for Animal Health (OIE), and Union against Tuberculosis and Lung
Disease published a roadmap to combat zoonotic TB (4). Bacillus Calmette Guérin (BCG) is the
only currently available vaccine against TB and potentially bTB, but confers incomplete and variable
protection against pulmonary TB in humans and against bTB in cattle (2, 5–7).
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Due to the ability of mycobacteria to survive the intracellular
environment of phagocytic cells, and the demonstration of
specific T cells as the pillar of acquired immunity to TB (8,
9), immunology studies and TB/bTB vaccine development to
date have focused on cell-mediated immunity. Indeed, there
is ample evidence that the cellular response is necessary for
protection, notably the increased susceptibility to TB in mice
and humans lacking elements of T cell immunity (10–12).
T cell responses to BCG vaccination have been described,
indicating the induction of robust Th1 responses in adults and
infants (13, 14). However, the association between vaccine-
induced cell-mediated immunity and protection against TB is
unclear (15, 16). The TB vaccine candidate MVA85A did not
demonstrate protective efficacy in a recent Phase IIb trial despite
inducing an IFNγ-secreting CD4+ T cell response (17). It is
not known whether protection requires a more potent cellular
response or qualitatively different immunogenicity. A role for
unconventional T cells and trained innate immunity in BCG-
mediated protection against TB has recently been proposed
(18, 19), as well as the potential involvement of humoral
immunity (20).
The humoral immune response in the context of TB and
bTB has been understudied, but recent evidence suggests that
B cells and antibodies may play a more significant role than
previously appreciated (20, 21). An antibody response to the
Ag85 complex was associated with superior outcome in a
cohort of M.tb-infected Mexican Indians (22). Furthermore,
low titers of antibodies against the mycobacteria surface
glycolipid lipoarabinomannan (LAM) have been associated with
disseminated TB in children (23), and some evidence suggests
that monoclonal antibodies against arabinomannan (AM; the
sugar component of LAM) are protective in mouse infection
models (24, 25). Lu et al. recently applied a systems serology
approach to identify antibody features that distinguished active
TB patients from individuals with latent M.tb infection (LTBI),
indicating a role for antibody effector functions in control of
infection (26). Exposed but healthy healthcare workers have also
been shown to make antibodies that offer moderate protection
against M.tb infection in both mouse aerosol challenge and in
vitromodels (27).
The antibody response to BCG vaccination has widely been
considered of little relevance to protection (13). However, in a
recent post-hoc correlates of risk analysis using samples from
the MVA85A efficacy trial, levels of Ag85A-specific IgG were
associated with reduced risk of TB disease in BCG-vaccinated
South African infants (28). Though increased following
MVA85A vaccination in the BCG-MVA85A group, levels of
these antibodies were also increased in the BCG-only placebo
group at this time-point, suggesting that protective antibodies
may be induced by BCG vaccination (28). Potential mechanisms
of antibody-mediated immunity against M.tb include enhanced
phagocytosis, increased phagolysosome formation, bacterial
neutralization, enhanced inflammasome activation, and
enhanced cytotoxic NK cell activity (29). Antibodies may also
interact with T cells to promote immunity, for example through
forming bacterial-antibody complexes that result in increased
processing and presentation of M.tb antigens to CD4+ T cells
by phagocytes, thus increasing T cell activation and enhancing
cytotoxic responses (29).
We review what is known about the humoral immune
response to BCG vaccination and re-vaccination across species,
including evidence for the induction of specific B cells and
antibodies and how these may relate to protection from TB or
bTB.We consider how factors such as BCG strain, manufacturing
methodology and route of administration influence the humoral
response, as well as the immunomodulatory effects of BCG
vaccination on non-specific humoral immunity. Insights into the
BCG-induced specific immune response may aid in informing
the design of an efficacious new TB vaccine which could
benefit from the targeting of humoral, as well as cell-mediated,
immunity. Understanding the off-target effects of BCG is also
important in the context of TB vaccine development, as novel
candidates in the current pipeline include both homologous and
heterologous BCG prime-boost regimens. Understanding the
mechanisms of non-specific immunity opens the possibility of
replicating or boosting beneficial responses to the host advantage,
or conversely of avoiding exacerbation of undesirable effects.
THE B CELL RESPONSE TO BCG
VACCINATION
B cells are observed in the lungs of TB patients, in the granulomas
of mice and non-human primates (NHPs) infected with M.tb,
and in cattle infected with M.bovis; these cells may act to
orchestrate and modulate the immune environment of the
infected lung (30–33). There is evidence of a role for B cells
in the granuloma producing M.tb-specific antibodies, acting as
antigen presenting cells (APCs) and reducing immunopathology
(32, 34, 35). Humans with pulmonary TB disease have been
shown to have lower peripheral B cell counts than asymptomatic
individuals with or withoutM.tb infection (36, 37). Vordermeier
et al. demonstrated an increased susceptibility to TB in B cell
deficient mice, although interestingly specific T cell responses
or protection conferred by BCG vaccination were not impaired
(38). Bosio et al. also reported that although B cell deficient mice
had comparable bacterial loads in the lungs following low-dose
infection with anM.tb clinical isolate, there was less severe lesion
formation and delayed dissemination of bacteria (39). It was later
shown that adoptive transfer of B cells into B cell knock-out
(KO) mice reversed the enhanced susceptibility to infection and
immunopathology observed (40). However, others have reported
no role for B cells in such models, which may reflect differences
in genetic backgrounds or strain and dose of M.tb used for
infection (39–42). The B cell compartment may even be involved
in disease progression, with an abundance of antibodies in sera
of patients with active disease suggesting that B cells are involved
in immunopathology (34), although the direction of causality
is unclear.
There is a paucity of literature on the B cell response to BCG
vaccination (13), although it has been demonstrated in mice that
B cell deficiency results in a diminished BCG vaccine-induced
Th1 response. Using a series of elegant experiments, the authors
proposed that B cells regulate neutrophilia duringM.tb infection
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and BCG vaccination by modulating the IL-17 response, and
that exuberant early neutrophilia (as observed in B cell deficient
mice) can adversely affect the vaccine-induced Th1 response by
impairment of dendritic cell (DC) migration to draining lymph
nodes, thus compromising CD4+ T cell priming (43).
A clinical study of 79 BCG-vaccinated and 14 unvaccinated
human volunteers found a significantly higher frequency of
PPD-specific memory B cells in PBMC from BCG-vaccinated
compared with unvaccinated volunteers (44). A lack of B cell
reactivity to either ESAT-6 or CFP-10 indicated that the increased
B cell response was not due to M.tb exposure. Donors received
BCG vaccination between 13 and 45 years prior to enrolment,
suggesting a long duration of the memory B cell response (44).
Conversely, in a randomized trial of 118Danish infants, there was
limited overall impact of neonatal BCG vaccination on a range of
measured B or T cell subset frequencies (45). However, it should
be noted that proportions of cells present in the peripheral blood
may not correlate linearly with specific immunity, and that effects
of antigen-specific cells may be masked where total populations
are measured.
THE SPECIFIC ANTIBODY RESPONSE TO
BCG VACCINATION
BCG Vaccination in Humans
There have been several studies measuring the specific antibody
response to BCG vaccination, a summary of which is provided in
Table 1. Early investigations utilized haemagglutination assays;
the first serodiagnostic test for TB described by Middlebrook
and Dubos in 1948 (78). Lagercrantz and Enell reported a large
study of 248 healthy Swedish children aged 8–15 years who
were BCG-vaccinated during their first year at school. Sixty-five
percent of the children had a haemagglutination titer of at least
1/8; a level comparable to that observed during M.tb infection
(46). Titer values at 3 months post-vaccination were significantly
higher than at 1–5 years post-vaccination, and were higher than
those found in children vaccinated at birth (46, 79). While other
studies in the 1950s using this assay failed to observe elevated
antibody activity following routine BCG vaccination (61), some
achieved positive results using alternative methods such as agar
gel diffusion and the bentonite flocculation test (47, 80).
The 1980s saw the development of an enzyme-linked
immunosorbent assay (ELISA) to measure antibody responses in
TB using plasma-membrane antigen fromM.tb (62). In addition
to investigating the activity of specific antibody in sera from TB
cases, Krambovitis considered the effect of BCG vaccination. Sera
were collected from five healthy TST negative adults at baseline
and 2 months post-BCG vaccination, and from a further two
adults at 2 years post-vaccination. There was no marked change
in specific IgG following vaccination in any of the volunteers,
although the small sample size is a notable limitation (62).
Consistent with this finding, there was no effect of previous BCG
vaccination on the levels of M.tb-specific IgG, IgM, or IgA by
ELISA in a separate study of 250 healthy volunteers (63).
However, later studies have more frequently observed
induction of specific antibody following BCG vaccination.
Turneer et al. reported a small but significant increase in levels of
both IgM and IgG following BCG vaccination in 75 adults using
a PPD-specific ELISA (48). In a study of 66 infants in Turkey, half
of whom received BCG vaccination in the first month and half in
the second month after birth, there was a significant increase in
PPD-specific IgM during the 15 month post-vaccination study
period with a higher titer at 2 and 4 months post-vaccination
in infants who were vaccinated in the second month of life.
IgG levels decreased at 2 months post-vaccination (which the
authors propose may be due to loss of maternally-transferred
antibody) but rose progressively thereafter (49). In a separate
study of 50 Indian children aged 1–10 years, there were
significantly higher levels of antibody to BCG-CF in BCG-
vaccinated compared with unvaccinated children or TB patients,
which were directed mostly toward the low molecular weight
proteins (51). Nabeshima and colleagues reported a significant
increase in antibodies directed against anti-tuberculous
glycolipid antigen (TBGL) at 2, 4, and 8 weeks following
BCG vaccination in 20 TST-negative Japanese healthcare
workers, although antibody levels had reduced by 1 year
post-vaccination (50).
Brown et al. went on to investigate antigenic targets of
specific antibodies in serum from subjects before and after
BCG vaccination and from TB patients, conducting ELISAs
with 20 different mycobacterial antigen preparations including
recombinant MPT63, MPT64, KatG, MPT51, ESAT-6, MTC28,
14kDa protein, 38kDa protein, CFP-10, TbDP, LAM, and Ag85.
Only LAM-reactive IgG was significantly increased among BCG-
vaccinated subjects compared with a PPD-negative control
group. The proportion of subjects with positive LAM responses
in the BCG-vaccinated group was similar to that in the active
TB group (52). Given that LAM is a major component of
the mycobacterial cell wall and has several immunosuppressive
effects that favor mycobacterial survival in the host (including
downregulation of DC function through interaction with the
DC-SIGN receptor), it follows that neutralizing antibodies to
LAM or its component AM may contribute to host defense
against mycobacterial infection (81, 82). Indeed, studies have
now indicated a protective role formonoclonal antibodies against
AM, and partial protection conferred by antibodies induced by
vaccination with AM-protein conjugates (25, 83). Furthermore,
an inverse correlation between the titer of LAM-specific
antibodies and risk of disseminated disease has been reported in
humans (23).
De Vallière et al. also reported significant induction of
LAM-specific IgG following both primary and secondary BCG
vaccination in 10 healthy volunteers (53). To our knowledge, this
is one of only two studies to have investigated the functional
mechanism of action of BCG-induced antibodies. Using GFP-
expressing BCG, it was demonstrated that internalization
of BCG by neutrophils and monocytes/macrophages was
significantly enhanced using post-vaccination compared with
pre-vaccination serum (53). Furthermore, the inhibitory effects
of these phagocytic cells on mycobacterial growth were
significantly enhanced by BCG-induced antibodies; an effect
which was reversed by preabsorption of IgG. Vaccine-induced
antibodies also enhanced proliferation and IFN-γ production in
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TABLE 1 | Summary of studies discussed in this review measuring specific antibody responses to BCG by route of administration.




• Positive haemagglutination titers in 65% of Swedish
schoolchildren following BCG vaccination (46).
• Increase in specific Abs following BCG vaccination using
the gel diffusion technique (47).
• Increase in PPD-specific IgM and IgG following BCG
vaccination in 75 adults (48).
• Increase in PPD-specific IgM and IgG during 15 months
post-BCG vaccination in 66 infants (49).
• Increase in TBGL-specific Abs following BCG
vaccination in 20 healthcare workers (50).
• Higher levels of BCG-CF specific Abs in
BCG-vaccinated Indian children vs. unvaccinated (51).
• Increased LAM-specific IgG in BCG-vaccinated
compared with unvaccinated volunteers (52).
• Induction of LAM-specific IgG following primary and
secondary BCG vaccination in 10 adults (53).
• Significant increase in AM-specific IgG at 4–8 weeks
post-BCG vaccination in UK adults (54).
• Levels of anti-CFP IgG increased following SC BCG
vaccination in a dose-dependent manner (55).
• Induction of IgG following vaccination with BCG or a
proteoliposome from BCG compared with PBS (56).
• Mice re-vaccinated with BCG show increased titer of
anti-BCG IgG (57, 58).
• Induction of LAM-specific IgG following BCG vaccination
vs. sham vaccination in guinea pigs (59).
• Weak specific IgG response following BCG vaccination
in rhesus (but not cynomolgus) macaques (60).
• Lack of circulating Abs after BCG immunization using
the globin titration technique (61).
• No marked changes in specific IgG at 2 months or 2
years post-BCG vaccination in 5 volunteers (62).
• No effect of BCG vaccination on levels of M.tb-specific
IgM, IgG or IgA in 250 volunteers (63).
• Low/absent Ab responses to M.bovis culture filtrate
following low- or medium-dose BCG vaccine (64).
• No induction of Abs to M.bovis culture filtrate following
primary/secondary BCG vaccination (65).
• No IgG responses to any tested antigens for 7 weeks
post BCG re-vaccination in calves (66).
• No detectable Abs in bovine neonates for 13 weeks
post BCG vaccination (67).
• No differences in Ab responses between naïve calves
and those vaccinated with live/inactivated BCG (68).
• Specific Ab levels not different between
BCG-vaccinated, re-vaccinated or unvaccinated
cattle (69).
Oral • Increased LAM-specific IgA in tears post primary and
secondary oral BCG vaccination (52).
• Induction of specific IgG following oral BCG
vaccination (70).
• Induction of PPD-specific IgG, IgM and IgA after oral
vaccination with various BCG strains (71).
• No increase in PPD-B or MPB83 specific Abs in wild
boar piglets following oral BCG vaccine (72).
Respiratory Intranasal (IN) • Higher levels of IgA in lungs following IN BCG compared
with SC vaccinated or naïve mice (73).
• Higher specific IgA, IgG1 and IgG2a Abs in nasal lavage
following IN BCG vs. SC or naïve (74).
Aerosol • Increased anti-PPD IgG titers following standard or
low-dose aerosol BCG vaccination in NHPs (75).
Pulmonary • IgA significantly increased in the BAL following
endobronchial compared with ID BCG (76).
Intravenous (IV) • Increased serum IgM, IgG and IgA following BCG by IV
route but not IC or aerosol routes (77).
• IgG and IgM responses at 1 month post-primary IV BCG
boosted by IV BCG re-vaccination (71).
Human studies are indicated by black text, cattle studies are indicated by blue text, murine studies are indicated by red text and non-human primate studies are indicated by green text.
Studies in any other species are indicated by light blue text.
mycobacterium-specific CD4+ and CD8+ T cells, highlighting
interdependence between the humoral and cellular arms (53).
Similarly, Chen et al. observed a significant increase in AM-
specific IgG at 4–8 weeks post-BCG vaccination which was
able to opsonize BCG and M.tb. When BCG was opsonized
with post-vaccination sera, there was significant enhancement
of phagocytosis, phagolysosomal fusion and intracellular growth
inhibition. Reduction of BCG growth in THP-1 cells correlated
significantly with post-vaccination AM-specific IgG, suggesting a
role for an FcγR-mediated effect (54). Such evidence supports a
protective function for BCG-induced antibodies, as summarized
in Table 2.
BCG Vaccination in Cattle
Induction of specific antibody following BCG vaccination is
rarely observed in cattle, despite BCG being similarly partially
protective in this species. Buddle et al. vaccinated 20 calves with
BCG within 8 h of birth, 10 of which received a BCG boost at
6 weeks of age. A further 10 calves received BCG vaccination
at 6 weeks only, and 10 matched animals were unvaccinated
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TABLE 2 | Summary of studies discussed in this review providing evidence for or against a protective function of BCG-induced antibodies.
Evidence supporting a protective function of BCG-induced antibody Evidence not supporting a protective function of BCG-induced antibody
Enhanced internalization and growth inhibition of BCG-GFP by phagocytes
incubated with post- vs. pre-BCG vaccination serum (53).
Enhanced phagocytosis, phagolysosomal fusion and intracellular growth
inhibition when BCG opsonized with post- vs. pre-BCG vaccination serum (54).
Levels of Ag85A-specific IgG associated with reduced risk of TB disease in
BCG-vaccinated South African infants (28).
BCG vaccination by endobronchial installation elicited superior protection from
repeated low-dose M.tb challenge compared with ID BCG, and IgA was a
correlate of local protective immunity (76).
BCG vaccination induces Abs against LAM and its component AM. These Abs
contribute to host defense against mycobacterial infection, and monoclonal Abs
against AM have a protective role in mice (23–25).
No significant reduction in bacterial burden following M.tb challenge when serum
transferred from BCG-vaccinated mice (84).
Levels of anti-CFP IgG increased following BCG vaccination in a dose-dependent
manner in mice but no influence of dose on protection following M.tb challenge (55).
No correlation observed between Ab levels and stimulation of protective immunity in
a study of different strains of BCG (71).
M.tb-specific Ab response observed in rhesus but not cynomolgus macaques
following BCG vaccination, but cynomolgus macaques better protected against
M.tb challenge (60).
BCG vaccination partially protective in cattle, but most reports indicate poor or no
induction of specific Ab (64–68, 85).
Human studies are indicated by black text, cattle studies are indicated by blue text, murine studies are indicated by red text and non-human primate studies are indicated by green text.
controls (65). There was no induction of antibody to M.bovis
culture filtrate in any group at 2, 4, 6, 9, or 12 weeks of age. There
was, however, a significant increase in antibody levels in all of the
animals following challenge withM.bovis (65). Additional studies
by the same authors reported that antibody responses toM.bovis
culture filtrate were low or absent in all groups following low- and
medium-dose BCG vaccination and subsequent challenge with
M.bovis, and following BCG vaccination by the respiratory or
subcutaneous (SC) routes (64, 85).
Lyashchenko et al. described a study of six calves aged 6
months that received two immunisations with BCG Pasteur
6 weeks apart. No IgG responses were detected to any of
the antigens tested (ESAT-6, CFP-10, MPB70, MBP59, MPB64,
MPB83, Acr1, or PstS-1) for 7 weeks post-booster vaccination
(66). Furthermore, in a study of 12 healthy bovine neonates aged
under 1 month in Ethiopia, there was no detectable antibody
in the naïve or BCG-vaccinated groups for 13 weeks post-
vaccination (67). In a more recent report of 24 healthy mixed-
breed Bos taurus calves aged 4–6 months of age, animals were
vaccinated with either live or inactivated BCG. There were no
significant differences in the antibody responses by IDEXX TB
ELISA between naïve animals and those vaccinated with live or
inactivated BCG for 9 weeks post-vaccination (68).
It may be of importance that all of these studies were
conducted in young calves. When LAM-specific IgG responses
to primary and secondary BCG vaccination were measured
in calves and young adults, the young adults demonstrated a
significant increase in antibody at 9 and 11 weeks post primary
vaccination and 1 and 3 weeks after secondary vaccination,
while such a response was absent in the calves. Furthermore,
PPD-B stimulated cells from vaccinated young adults secreted
significantly more antibody than cells from unvaccinated calves
in a cell culture system (86). This suggests that young calves
may be limited in their capacity to mount an antibody response
to BCG, possibly associated with immaturity of the neonatal
immune system (87). Furthermore, the passive transfer of
maternal antibody to neonates may mask vaccine responses or
actively interfere with postnatal activation of the calf ’s own
immune system and capacity to mount a protective response to
vaccination or infection (87–89).
BCG Vaccination in Preclinical Models
Preclinical models offer the opportunity to explore novel vaccine
candidates or regimens, and to relate induced immune responses
to protection from subsequent experimental mycobacterial
challenge. In a murine study comparing different doses of BCG,
levels of anti-CFP IgG increased following vaccination at all
doses, with the highest levels seen in mice vaccinated with
the highest dose of BCG, although there was no influence of
dose on protection following M.tb challenge (55). A recent
murine study of an AM-protein conjugate vaccine demonstrated
induction of an AM-specific antibody response, prolonged
survival and enhanced control of extrapulmonary dissemination
in immunized compared with control animals (84). Interestingly,
a serum passive transfer experiment resulted in a significant
reduction in lung and spleen bacterial burden following transfer
of serum from mice vaccinated with the AM conjugate vaccine
constructs but not from mice vaccinated with BCG (84). In a
study of mice vaccinated with either PBS, BCG, a proteoliposome
from BCG (PLBCG) or PLBCG with alum hydroxide (PLBCG-
AL), there was significant induction of specific IgG (all subclasses
combined) and IgG1 in all groups receiving vaccines compared
with PBS, and significant induction of IgG2a in the BCG-
vaccinated group only at 6 weeks post-vaccination (56).
Guinea pigs are a useful model for TB due to ability
to reproducibly infect animals with M.tb and remarkable
similarities to humans in the course of disease following
pulmonary infection (90). Consistent with findings in humans,
significant induction of LAM-specific IgG has been reported
in guinea pigs who had been BCG-vaccinated compared with
those receiving a sham vaccination (91). Romain et al. collected
sera from BCG-vaccinated guinea pigs and used it to detect
mycobacterial antigens present in BCG or M.tb culture medium
filtrate which are recognized by antibodies raised against
live BCG. They identified and purified a complex of 45- and
47-kDa major molecules (Apa), a cell-surface adhesion and
secretory glycoprotein produced by all members of the M.tb
complex, which was found to be an immunodominant target
triggering an antibody response following BCG vaccination
(59). Several Apa-subunit or DNA vaccines have since
been shown to confer significant protection against M.tb
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challenge, consistent across vaccination strategies and animal
models (92–96).
While non-human primates (NHPs) are considered the most
relevant animalmodel for human TB vaccine development due to
susceptibility toM.tb infection and partial protectiveness of BCG
(97, 98), there is very little literature on the antibody response
to BCG in this model. An early study described detection
of antibody in monkeys following BCG vaccination or M.tb
infection using a gel double-diffusion test (47). In a more recent
comparison of BCG vaccination in different species, a weakM.tb-
specific IgG response was observed in rhesus but not cynomolgus
macaques at 14 weeks post-BCG vaccination (although it should
be noted that animals were treated with a 3-week course of daily
oral isoniazid and rifadin treatment at 8 weeks post-vaccination).
Interestingly, cynomolgus macaques appeared better protected
against subsequent M.tb challenge, which draws into question
the relevance of the specific IgG response to protection (60).
An increase in anti-PPD antibody titers following aerosol BCG
vaccination in macaques has recently been reported, as described
in the section Aerosol BCG (75).
BCG Re-vaccination
Several human epidemiological studies, as well as a large
randomized controlled trial in Brazil, have previously indicated
that BCG re-vaccination confers no additional protection to
neonatal vaccination (99–101), as well as a large randomized
controlled trial in Brazil (100). However, a recent Phase II
prevention-of-infection trial in South African adolescents found
that while BCG re-vaccination did not demonstrate efficacy in
preventing initial M.tb infection (defined as QFT conversion at
an IFN-γ level of ≥0.35 IU per ml after day 84), it did result in
significantly reduced rates of sustained QFT conversion (defined
as three consecutive positive QFT results after day 84) (102).
The authors suggest that as initial acquisition of infection is not
averted by the innate immune response, antigen is trafficked
to the draining lymph nodes triggering adaptive immunity (as
indicated by initial QFT conversion), followed by enhanced
bacterial control or clearance in protected individuals (102). The
inconsistency in outcomes between this and previous BCG re-
vaccination trials may reflect different enrolment criteria, as the
recent study excluded adolescents who were not QFT-negative at
baseline and BCG efficacy is thought to be greatest in individuals
without previous mycobacterial exposure (103). These findings
have fuelled renewed interest in the potential utility of BCG re-
vaccination, although it is not clear to what extent cellular and/or
humoral immunity contribute to this protection.
In the murine model, mice vaccinated with a repeat dose
of BCG demonstrated an increased titer of anti-BCG IgG
(57, 58). In a study of naïve and historically BCG-vaccinated
UK volunteers, there was no significant difference between
groups in the total IgG response at baseline or 4 weeks after
BCG vaccination (which represented a re-vaccination for the
historically BCG-vaccinated individuals). However, the group
receiving a re-vaccination had significantly higher levels of IgG2
at both time-points (54). Increases in AM-specific IgA and
IgM titers were significant after secondary but not primary
vaccination, and re-vaccination induced more pronounced IgG
responses to AM oligosaccharide (OS) epitopes than primary
vaccination (54). In the de Vallière et al. study described in the
section BCG Vaccination in Humans, 8 of the 10 volunteers
were given a BCG re-vaccination 6 months following primary
vaccination. There was a significant increase in levels of LAM-
specific IgG following primary vaccination which was further
increased at 8 and 28 weeks post-boost. As described, these
antibodies were found to be capable of enhancing both innate and
cell-mediated immune responses to mycobacteria (53).
Use of an in vitro model of human PBMC induced with a
repeat dose of BCG at 24 and 72 h of cell culture demonstrated
increased anti-BCG IgG levels in supernatants compared to the
pre-boost and control groups (104). Re-vaccination of cattle
with BCG 2 years after first vaccination restored protection
from M.bovis challenge compared with calves receiving only
a single vaccination 2.5 years previously (69). However, the
serum antibody responses to M.bovis culture filtrate protein
or Ag85A peptides measured following re-vaccination and
challenge were not significantly different between the BCG-
vaccinated, re-vaccinated or unvaccinated groups. Interestingly,
immune responses in cattle re-vaccinated with TB protein
vaccines were biased toward induction of antibody, but this
was not associated with improved protection from in vivo
challenge (69).
BCG BY OTHER ROUTES OF
ADMINISTRATION
Oral BCG
BCG was originally administered by the oral route, but this
was largely replaced by intradermal vaccination following (a)
the observation that oral administration produced no allergic
skin response (considered at the time evidence of immunity
against TB), (b) the Lübeck disaster (when neonates were
mistakenly given oral BCG vaccine contaminated withM.tb) and
(c) association with cervical adenitis (105, 106). However, oral
BCG has been shown to induce greater mucosal and systemic
immune responses compared with intradermal vaccination in
mice (107), and there has been renewed interest in this route
of delivery (106). Lagranderie et al. reported the induction of
PPD-specific IgG, IgM, and IgA in sera, intestinal secretions and
BAL fluids of mice following oral vaccination with various BCG
strains (71).
In the Brown et al. study described in the section BCG
Vaccination in Humans (52), mucosal specimens were harvested
from 8 volunteers before and after two oral BCG vaccinations
administered at an interval of 6 months. There was a significant
increase in LAM-specific (but not Ag85- or M.tb whole lysate-
specific) IgA antibodies in tears at 6 months post-primary oral
BCG vaccination and at 1 week and 6 weeks post-secondary
oral BCG vaccination (52). A second study reported induction of
specific IgG that peaked between 10 and 14 days after oral BCG
vaccination. Two volunteers who received boosting with oral
BCG showed an alteration in the humoral immune response with
a shift of isotype from IgG to IgA, independent of the route used
for primary vaccination (70). This supports the suggestion by
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Hoft et al. that a combination of intradermal and oral routes for
BCG vaccination may induce mucosal and systemic immunity
against initial infection and systemic progression (108).
Significant wildlife reservoir hosts exist for M.bovis infection
of cattle including badgers in the UK, white-tailed deer in the
US, and wild boar and red deer in Spain (2). Oral delivery of
vaccines would be the most practical and cost-effective means
of vaccinating wildlife, and oral vaccines have been successfully
used to protect foxes against rabies (109). In a study of 20
wild boar piglets aged 3–4 months, there was no increase in
PPD-B or MPB83 antigen-specific antibody levels following oral
BCG vaccination for 8 weeks post-vaccination (72). However,
oral vaccination with heat-inactivated M.bovis in wild boar has
been shown to induce specific antibody responses that may be
associated with protection fromM.bovis challenge (72, 110).
Respiratory BCG
Since TB is primarily a pulmonary infection, targeting delivery
of BCG directly to the respiratory mucosa (either by intranasal,
aerosol or pulmonary administration) may be physiologically
and immunologically beneficial (111). Furthermore, intranasal
or aerosol routes could offer practical advantages for vaccine
administration and negate the risk of cross-contamination due
to needle re-use, particularly in developing countries.
Intranasal BCG
Recent studies have demonstrated that intranasal (IN)
vaccination with BCG results in superior protection of mice
against challenge with M.tb or M.bovis (112, 113). Intranasally
administered BCG has been shown to induce secretion of total
(specific and non-specific) IgA and M.tb-specific IgA in the
lungs in an IL-17A-dependent manner at levels significantly
higher than in unvaccinated mice or those vaccinated with BCG
subcutaneously. This was associated with protection against
pulmonary M.tb challenge following IN but not subcutaneous
BCG in the TB-susceptible DBA/2 mouse strain (73). In a
separate study in BALB/c mice, IN BCG induced significantly
higher levels of specific IgA, IgG1, and IgG2a antibodies in
the nasal lavage compared with subcutaneously vaccinated or
unvaccinated mice and resulted in a lower bacterial load in the
lungs following M.tb challenge (74). However, it has been noted
that extent of granuloma formation is associated with level of
protection in the lungs following IN BCG vaccination, and that
dosage needs balancing to avoid undue pathology (114). The use
of IN vaccination in humans has raised safety concerns following
association of facial nerve paralysis (Bell’s palsy) with three
separate IN vaccines administered with the E.coli heat labile
toxin adjuvant (ELT) (115, 116).
Aerosol BCG
The aerosol route of vaccination has been explored for other
respiratory pathogens including influenza and measles, in
which boosting with an aerosolised vaccine evoked a stronger
and more durable antibody response than injected measles
vaccine and was effective and well-tolerated (117, 118). BCG
administered by aerosol has been demonstrated to induce a
greater degree of protection against challenge with virulent
M.tb than subcutaneous BCG vaccination in Rhesus macaques
and guinea pigs (119, 120). In a separate NHP study, median
anti-PPD IgG titers in the serum increased following aerosol
BCG vaccination at both a standard and low-dose relative to
baseline (75). Although aerosol vaccination with BCG has been
described in humans, the antibody response was not measured
(121). Interestingly, anti-vector antibodies to the TB vaccine
candidate MVA85A were reported in the serum after ID but
not aerosol administration in humans, suggesting that aerosol
vaccination may overcome detrimental pre-existing humoral
immunity against the vaccine vector (122).
Pulmonary BCG
The intratracheal (IT) and endobronchial routes may be favored
for preclinical respiratory BCG studies as they allow for accurate
delivery of defined vaccine doses. Although IT BCG vaccination
in mice has been shown to confer superior protection to the
SC route, to our knowledge there are no descriptions of the
humoral response (123). In cattle, Buddle et al. reported superior
protection to M.bovis challenge following BCG vaccination by
the IT route compared with the SC route or with ID vaccination
using heat-killedM.vaccae. However, the proportions of animals
showing positive responses in an antibody ELISA againstM.bovis
culture filtrate did not differ between groups (85).
Dijkman et al. conducted a controlled NHP study in which
BCG vaccination was administered by the standard ID route
or by endobronchial installation into the left lower lung lobe
(BCG.muc) (76). There was a significant but modest increase
in PPD-specific pan-immunoglobulin in the serum following
BCG vaccination by both routes compared with unvaccinated
controls. IgA was significantly increased by more than 1 log in
the BAL (but not the serum) at 8 weeks following BCG.muc
compared with unvaccinated controls or animals receiving ID
BCG vaccination. BCG.muc was able to prevent infection with
repeated low-dose M.tb challenge (RLD), as evidenced by lack
of IGRA conversion or TB-associated pathology in some of the
animals. BCG.muc also elicited superior protection from RLD
compared with ID BCG (∼1.5 vs. ∼1 log reduction in primary
lung lobe CFU and ∼3 vs. ∼1 log reduction in BAL CFU), and
importantly IgA was identified as a correlate of local protective
immunity (76). IgA is the most abundantly produced natural
antibody isotype in mucosal tissue, and may play an important
role in the host’s early defense against pathogens invading the
respiratory tract (124). Indeed, it has been shown that IgA can
prevent the adsorption of bacteria at the mucosal epithelium
(125–127) and block the entrance of mycobacteria into the lungs
(128). While endobronchial installation may not be a deployable
vaccine strategy in humans, the protective signal offers a valuable
opportunity to identify immune correlates of protection to aid in
development of improved TB vaccines.
Intravenous BCG
There has been a resurgence of interest in intravenous (IV) BCG
given the recent NHP study demonstrating superior protection
against virulent M.tb challenge following vaccination by this
route compared with ID or ID with an intratracheal mucosal
boost (ID+IT) (129). This finding supports several reports
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published in the 1970s indicating improved protection conferred
by the IV route of administration (119, 130–132). One early NHP
study comparing BCG administered intracutaneously (IC), IV or
by aerosol inhalation detected precipitating antibodies during the
post-vaccination period only in the IV group; this increase was
associated with marked increases in serum IgG, IgA, and IgM,
although corresponding levels of protection were not measured
(77). IgG, IgA, and IgM PPD-specific antibody responses were
also analyzed in mice receiving IV BCG vaccination and re-
vaccination 1 month later. IgG and IgM responses were detected
at 1 month post-primary BCG vaccination and were further
boosted by re-vaccination, remaining stable until the end of the
experiment. IgA responses remained low even after two BCG
vaccinations (71).
VARIATION IN BCG EFFICACY
In addition to directing improved TB vaccine design, better
characterization of the overall BCG-induced immune response
may aid in understanding the observed variability in vaccine
efficacy. This is essential if we are to avoid a new generation
of vaccines being subject to the same pitfall. Although previous
exposure to non-tuberculous mycobacteria (NTM) resulting
in “masking” or “blocking” of the BCG-induced immune
response is the leading hypothesis for variation in vaccine
efficacy, a range of other factors such as genetic or nutritional
differences between host populations, environmental influences,
and viral or helminth infections at time of vaccination have been
implicated (5, 133, 134).
Variation in BCG strain may also play a role, with some
evidence of a divergence in protective immunity conferred by
different strains (135, 136). Interestingly, a comparative analysis
of human B cell epitopes based on BCG genomes indicated
strain-specific differences which the authors hypothesize may
contribute to variability in BCG vaccine efficacy (137). In one
study comparing oral immunization of mice using BCG Pasteur,
Glaxo, Japanese, Russian or Prague strains, the highest IgG and
IgA anti-PPD antibody responses were observed in sera of mice
immunized with the Pasteur and Russian strains (71). After IV
vaccination, the Japanese strain induced only very low levels of
anti-PPD specific antibodies compared with the other strains but
no correlation was observed between induction of antibody and
stimulation of protective immunity as measured by ability to
eliminate rBCG expressing β-glacatosidase (71).
Using the Moreau strain, Petricevich et al. investigated
whether differences in methodology for vaccine manufacture
influenced the capacity of BCG to induce a humoral immune
response in mice. They found that BCG bacilli cultured in
Sauton-asparagine medium multiplied more and induced a
stronger humoral immune response (with higher titers of
BCG-specific antibody and a higher number of antibody-
producing spleen cells) compared with bacilli grown in
Sauton-starch/bacto-peptone-enriched medium (138). The
mycobacterial capsule is enriched in polysaccharides and lipids
and includes some immunologically active secreted proteins
(139). Prados-Rosales et al. used specific antibodies to the major
capsule polysaccharides, AM and α-glucan, to demonstrate that
growing BCG in the presence of detergent strips the capsule.
While un-encapsulated BCG induced predominantly IgM
responses following vaccination, encapsulated BCG grown in
the absence of detergent was better at eliciting higher titers
of class-switched antibody. Encapsulated BCG was also more
effective at generating IFN-γ and polyfunctional T cell responses
and together this enhanced immunogenicity was associated with
a lower bacterial burden followingM.tb challenge (140).
OFF-TARGET HUMORAL
IMMUNOMODULATORY EFFECTS OF BCG
VACCINATION
Infectious Diseases and Heterologous
Vaccines
There is a growing body of literature proposing non-specific
benefits of BCG vaccination including a reduction in all-cause
infant mortality and protection against unrelated infectious
diseases (141–144). Although IV BCG has been reported to
protect mice against challenge with Babesia and Plasmodium
spp., this is not thought to be associated with antibody specific for
surface antigens of the parasites (145). Furthermore, resistance
of BCG-infected mice to superinfection with Salmonella
typhimurium is not associated with a greater or more rapid
antibody response (146). It is thought that protection beyond
the target pathogen could rather be promoted by heterologous
lymphocyte activation or innate immune memory (147).
Interestingly, in a recent trial in Denmark, BCG vaccination
was associated with a reduced rate of infant hospitalization
for infection, but only in infants of mothers who were BCG-
vaccinated (148). This observation was supported by a similar
finding in Guinea-Bissau, where the reduction in all-cause
mortality was 66% (95% CI, 33–83%) if the mother also had
a BCG scar (149). Vaccinating against measles in the presence
of maternal antibody is associated with reduced child mortality
(150), and it is possible that a similar mechanism acts to enhance
the non-specific effects of BCG vaccination. Indeed, studies
have demonstrated that maternal BCG vaccination modifies the
immunological response to BCG in the infant (151, 152). In
the BCG re-vaccination trial described in the section BCG Re-
vaccination, a decrease in unrelated respiratory tract infections
was observed in BCG re-vaccinated individuals compared with
the H4:IC31 vaccinated or placebo groups (102, 153). Although
the immune mechanism remains unclear, BCG re-vaccination,
like maternal priming, represents a situation in which the
presence of (possibly antibody-related) pre-existing immunity
enhances non-specific effects.
There is some evidence that BCG vaccination enhances
the humoral immune response to other unrelated childhood
vaccinations, essentially acting as an adjuvant. Ota et al. reported
that infants vaccinated at birth with BCG had, upon vaccination
against hepatitis, significantly higher levels of IgG against
hepatitis B vaccine antigens. Furthermore, BCG vaccination
given at the time of oral polio vaccine boosting improved
the antibody response to polio, indicating an effect of BCG
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at the systemic level (154). An Australian study of 56 BCG-
vaccinated and 52 non-BCG vaccinated infants found that
BCG vaccination was associated with significantly higher IgG
titers against pneumococcal capsular polysaccharide antigens,
H.influenzae type b polysaccharide and tetanus toxoid following
routine immunisations later in infancy (155). Conversely, in
a study of 300 children in a high-income setting, no overall
effect of neonatal BCG vaccination was observed on antibody
levels induced by the routine vaccinations DiTeKiPol/Act-Hib
and Prevnar 13. However, a possible enhancing effect of BCG
on antibodies against B. pertussis and all pneumococcal serotypes
was identified when stratifying by age of randomization to BCG
vaccination or no BCG vaccination suggesting that the timing of
BCG vaccination may be important (156).
Atopic Disorders and IgE
The hygiene hypothesis proposes that the increasing occurrence
of allergies in the developed world may be associated with
reduced incidence of microbial infections, including TB, which
would otherwise bias the developing immune system toward
a Th1 response. The resulting Th1-Th2 imbalance with an
increase in Th2 cells favors IgE antibody production and the
establishment of allergic reactivity (157). In such a situation, it
is plausible that BCG early in life could provide Th1 stimulation
that mimics mycobacterial infection and reduces the incidence
of atopy. Indeed, positive tuberculin responses were associated
with lower serum IgE levels, cytokine profiles biased toward a
Th1 type and lower incidence of asthma in a retrospective study
of over 800 Japanese schoolchildren (158). In Italian volunteers
with allergic rhinitis, there was a significant decrease in total
and allergen-specific IgE levels following BCG vaccination (159).
A further study indicated that BCG vaccination was associated
with downregulation of spontaneous and stimulated in vitro
IgE secretion from PBMC of atopic children with asthma
(160). Atopy (defined as skin test reactivity to Dermatophagoides
pteronyssinus, D. farinae or cockroach) was reduced in African
children given BCG vaccination early in infancy, although
IgE levels were not measured in this study (161). That BCG
vaccination is associated with a reduction in allergen-specific
antibodies and a beneficial effect on atopic disorders is supported
by several preclinical studies (162–165).
However, others report no marked effect of BCG vaccination
on IgE levels or risk of development or symptoms of atopic
disease (166–171). While there are several studies describing
repeated administration of inactivated BCG for the management
of asthma (172–174), a randomized double-blind placebo-
controlled study in adults with moderately severe asthma and
house dust mite allergy showed no efficacy of four injections
with heat-inactivated BCG and no reduction in IgE compared
with the placebo group (175). Differences in outcome may be
related to time of, or since, BCG vaccination (176, 177) or
host genetic factors (178, 179). Safety concerns have been raised
regarding the use of BCG as a tool for the prevention and therapy
of allergic airway disease, as Ahrens et al. noted that BCG-
induced suppression of Th2-type allergic airway inflammation
in the OVA-sensitized mouse also stimulated Th1-associated
neutrophilic airway inflammation (180).
Autoantibodies
Autoantibodies have been found at high frequency in the
blood of patients infected with mycobacteria (181), suggesting
cross-reactivity between mycobacterial and host antigens. A
recent study of sera obtained from healthy adults post-BCG
vaccination reported IgG recognition of host peptides that
peaked at 8 weeks post-vaccination and diminished over time
(182). IgG responses primarily demonstrated increased reactivity
to ion transporters, cytokine receptors, ribonucleoprotein and
enzymes. The authors suggest that the modification of the
host immunological and non-immunological landscape in this
way may influence disease-specific immune responses previously
reported in TB, autoimmune disease and cancer (182). Indeed,
autoantibodies associated with autoimmune diseases such as
systemic lupus erythematosus (SLE) have been shown to
recognize mycobacterial antigens (183, 184). In non-obese
diabetic (NOD) mice, heat-killed BCG was shown to prevent
diabetes but precipitated a systemic lupus erythematous (SLE)-
like syndrome associated with increased titers of antinuclear
autoantibodies (185).
Insulin-dependent diabetes mellitus, or type 1 diabetes
(T1D), is an autoimmune condition in which insulin-producing
pancreatic islet cells undergo immune-mediated destruction.
BCG vaccination has been reported to prevent the onset of
T1D in mice and result in clinical remission or a long-term
reduction in blood sugar levels in T1D patients (186–189). T1D is
a predominantly T cell-mediated disease, and the mechanism of
action of BCG in this context is thought to be through induction
of tumor necrosis factor (TNF) resulting in selective death of
autoreactive T cells and expansion of beneficial regulatory T
cells that restore immune balance (190). Autoantibodies may
also play a role and BCG vaccination has been associated
with a significant reduction of autoantibodies to the 65-kDa
isoform of glutamate decarboxylase (GAD65) and islet tyrosine
phosphatase (I-A2) in southern Indian diabetic patients (191).
However, a separate prospective study of German infants born
to parents with T1D found no evidence that BCG vaccination
reduced GAD65, I-A2 or insulin autoantibody levels by age 2
or 5 years, and suggested that neonatal BCG vaccination may
in fact accelerate progression from autoimmunity to diabetes
in autoantibody-positive children (192). Furthermore, BCG
vaccination has been linked to an increased risk of developing
high levels of anti-IA-2 autoantibodies, although the authors
note that the number of vaccinated children was relatively
small and not representative of the general population (193).
Outcomes have been shown to differ widely from individual to
individual (194).
Multiple sclerosis (MS) is an autoimmune-mediated
inflammatory disease affecting the central nervous system. It
has been postulated that BCG vaccination may be beneficial in
suppressing autoimmune responses in the animal model of MS
(experimental autoimmune encephalomyelitis) and human MS
(195, 196), and conversely that it could initiate autoimmunity
throughmolecular mimicry (197). Interestingly, a seroprevalence
study measuring antibodies against the host encephalitogenic
myelin oligodendrocyte glycoprotein (MOG)35−55 epitope
and two mycobacterial peptides sharing sequence homology
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showed a significant difference between MS patients and
healthy controls in levels of antibody positivity for MOG35−55
but not for the BCG-derived homologous peptides (198). A
possible role for antibody responses to mycobacterial hsp65
(and equivalent human or bacterial proteins) has been proposed
in rheumatoid arthritis (RA), although findings are conflicting
(199–201). Increased levels of anti-BCG antibodies have also
been reported in RA and SLE patients compared with healthy
controls (202), and BCG therapy for cancer has been associated
with systemic autoimmune phenomena such as inflammatory
arthritis or immune-related toxicity, likely through molecular
mimicry (203–205).
Cancer Immunotherapy
The relationship between mycobacteria and cancer was
first recognized almost a century ago, with animal studies
demonstrating that BCG-infected mice were resistant to
transplantation of tumor cells leading to the discovery of Tumor
Necrosis Factor (TNF) (206–208). Numerous attempts were
consequently made to apply BCG as a therapy for various
cancers including leukemia and melanoma; the efficacy of BCG
therapy for bladder cancer has since been confirmed and it is
now the standard of care for high-risk non-muscle-invasive
disease (209). It is generally considered that CD4+ and CD8+
T cells, NK cells and granulocytes are the main players in
mediating the immunotherapeutic effect of BCG in this context,
but important humoral factors have been identified and it is
possible that antibodies contribute to the immune activation
observed (210). While some early studies in melanoma and
bladder cancer patients reported an increase in BCG-specific
antibody following therapy which was tentatively associated
with reduced rates of recurrence (211–213), others did not
confirm these findings (214, 215). Interestingly, parenteral
exposure to BCG prior to intravesical treatment has been
associated with improved response to therapy, and patients with
sustained pre-existing immunity to BCG showed significant
improvement in recurrence-free survival (216). This is in
line with the observations regarding the beneficial effects of
maternal priming and BCG re-vaccination on non-specific
effects of BCG described in the section Infectious Diseases and
Heterologous Vaccines.
Antibodies raised against mycobacterial antigens with a
high degree of homology to proteins found on the surface of
tumor cells may be of direct relevance to clinical outcome.
Early work on cross-reactivity demonstrated that guinea pigs
immunized with BCG developed antibody in their sera to the
transplantable guinea pig hepatoma line 10 (but not line 1)
(217). The mycobacterial heat shock protein hsp65 induces
a strong cellular and humoral immune response, and hsp65
from BCG has been shown to enhance recognition of tumor-
associated antigens (218). It has been reported that titers of
IgG against hsp65 and the native protein P64 in bladder
cancer patients increase after BCG intravesical therapy, but that
increased antibody responses against P64 may be associated
with a higher rate of tumor recurrence (215, 219). In a
murine model of transplantable methylcholanthrene-induced
fibrosarcoma, BCG treatment of tumor-bearing mice stimulated
formation of antibodies against tumor-specific antigens but
these antibodies enhanced tumor growth (220). A summary
of the off-target humoral immunomodulatory effects (both
beneficial and detrimental) of BCG vaccination is provided
in Table 3.
CONCLUSIONS
Until relatively recently, a simplistic paradigm has prevailed of
a mutually-exclusive immunological duality with the cellular
and humoral arms of immunity conferring protection against
intracellular and extracellular pathogens respectively. However,
this was challenged by Casadevall and others who pointed
to a role for humoral immunity in preventing infection with
some intracellular pathogens (221). It is now recognized that
there is extensive synergy between the two arms of immunity
with, for example, B cells modulating the T cell response
via cytokine production and participating in T cell priming
through antigen capture and presentation (40, 222). A dual
requirement for both cell-mediated and humoral immunity in
the development of an effective response to both intracellular and
extracellular pathogens is increasingly recognized. Furthermore,
with accumulating evidence supporting a contribution of trained
innate immunity to protection (19), the key to a more successful
TB vaccine may lie in the stimulation of the innate immune
system and harnessing of humoral immunity in concert with a
potent cell-mediated response.
In light of this, together with recent evidence supporting
a role for antibodies in immunity against TB and questioning
the sufficiency of the cell-mediated response alone to confer
protection (15, 16, 26–28), understanding humoral immunity
in TB has become increasingly pertinent. As the only vaccine
currently available against TB, and offering partial protection
against the transmissible pulmonary form of disease, BCG
offers an opportunity to identify and characterize the protective
components of vaccine-induced humoral immunity. Such
insights may aid in the design of new more efficacious TB and
bTB vaccine candidates, especially when related to functional
properties in vitro and protection from mycobacterial challenge
or natural infection in vivo. Alternatively, given the recent
findings regarding the non-specific benefits of BCG (141–144),
the influence of maternal priming (148–152) and the efficacy
of BCG re-vaccination in reducing sustained infection (102),
control of the TB epidemic may in fact be achieved through wiser
use of the BCG vaccine itself.
However, the humoral immune response to BCG vaccination
remains poorly defined. Evidence for the induction of specific
antibody responses is variable and the relevance to protection
is unclear, as summarized in Table 2. Many of the cited studies
suffer from small sample sizes and unspecified/different sampling
time-points or duration of follow-up. Outcomes may also be
influenced by assay methods, dose and strain of BCG vaccine,
species/strain of animal or population of humans and baseline
characteristics such as mycobacterial exposure, co-infections or
genetic factors. Age at time of vaccination is also important; the
presence of maternal antibody in early infancy may complicate
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TABLE 3 | Summary of evidence for off-target humoral immunomodulatory effects of BCG vaccination discussed in this review.
Beneficial effect of BCG on humoral
immunity
No effect of BCG vaccination on
humoral immunity
Detrimental effect of BCG vaccination on
humoral immunity
Heterologous vaccines BCG vaccination results in higher levels of IgG
against hepB vaccine antigens upon hepB
vaccination (154).
BCG vaccination at time of polio vaccination
associated with improved Ab response to
polio (154).
BCG vaccination associated with increased
IgG against pneumococcal, H.influenzae and
tetanus antigen (155).
No effect of neonatal BCG vaccination on
Ab levels induced by DiTeKiPol/ Act-Hib
and Prevnar 13 (156).
Atopic disorders BCG vaccination associated with reduction in
allergen-specific Abs and beneficial effect on
atopy (162–165).
Positive tuberculin responses associated with
lower serum IgE levels and reduced
asthma (158).
Decrease in IgE levels following BCG
vaccination in patients with allergic
rhinitis (159).
Decrease in IgE secretion in vitro following BCG
vaccination in atopic children with
asthma (160).
No reduction in IgE levels and no marked
decrease in atopy or allergy in
BCG-vaccinated children (166–168).
No association between atopy or serum
IgE levels and tuberculin response/BCG
scar in Gambia (169).
Four injections of heat-inactivated BCG in
atopic adults showed no effect on IgE and
no efficacy (175).
BCG-induced suppression of Th2-type
inflammation in sensitized mice leads to
neutrophilic airway inflammation (180).
Autoimmune disease BCG vaccination associated with reduction of
GADA and I-A2 autoantibodies in
diabetics (191).
No BCG-induced reduction in GADA, I-A2
or IAA autoantibodies in infants of T1D
parents (192).
No difference in Abs specific for
BCG-derived MOG homologs in MS
patients vs. controls (198).
Heat-killed BCG in NOD mice precipitated a
SLE-like syndrome associated with
autoantibodies (185).
Neonatal BCG vaccination may accelerate
progression to diabetes in
autoantibody-positive children (192).
BCG vaccination linked to increased risk for
development of high levels of IA-2
autoantibodies (193).
Cancer immunotherapy Increase in BCG-specific Ab tentatively
associated with reduced cancer recurrence
(211–213).
Ab to transplantable guinea pig hepatoma line
10 induced in BCG-vaccinated guinea
pigs (217).
Enhanced recognition of tumor-associated
antigens induced by hsp65 from BCG (218).
Increased Ab responses against P64 induced
by BCG therapy associated with tumor
recurrence (215, 219).
Abs against tumor-specific antigens induced by
BCG therapy associated with enhanced tumor
growth (220).
BCG therapy associated (rarely) with systemic
autoimmune phenomena or immune-related
toxicity (203–205).
Human studies are indicated by black text, murine studies are indicated by red text and studies in any other species are indicated by light blue text.
studies of humoral immunity to neonatal vaccination and
durability of induced antibody responses is more limited than
at older ages. In particular, when literature is consolidated,
it is apparent that BCG-induced antibody is observed more
consistently in humans than cattle. However, findings in cattle,
at least in the earlier studies, may be confounded by the use of
high doses of BCG which are now known to be less effective
than lower doses, and that studies were often performed in
regions with very high prevalence of M.bovis or in neonatal
calves with immature immune systems and presence of maternal
antibody (2).
Recently, large randomized controlled trials using
standardized assays have more consistently observed induction
of antibody following BCG vaccination, with convincing
evidence for a functional role of LAM- or AM-specific IgG in
vitro (53, 54). It is clear from several studies that BCG induces
antibody directed against LAM and AM, and that vaccine
constructs based on these antigens can be protective in mice
(84). However, other antigen targets are not well-defined and
protective epitopes may not necessarily be on the cell surface,
be immunodominant or induce the highest antibody titers. This
area warrants further investigation, including consideration
of other measures of antibody efficacy such as avidity and
affinity which may associate more strongly with protection than
titer alone.
Inability to observe a correlation with protection does not
rule out antibody responses as a contributing factor; humoral
immunity may be necessary but not sufficient for protection, or
may be relevant for some hosts but not others. Furthermore,
the overwhelming majority of studies investigating anti-
mycobacterial humoral responses have sampled the periphery,
which may not reflect the situation at the site of infection.
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As different routes of vaccination are explored, particularly
targeting the respiratory mucosa, the induction of localized
humoral immunity may become increasingly relevant. IgA, the
predominant antibody isotype present in the mucosal tissue, is
widely considered to be involved in defense against viral and
bacterial infections at these sites, and it has been demonstrated
that IgA-deficient mice have increased susceptibility to IN
mycobacterial infection (223). Furthermore, Balu et al. reported
protection against M.tb in mice using an immunotherapeutic
human IgA monoclonal antibody (224).
Better characterization of the BCG-induced immune response
may also aid in understanding the observed variability in vaccine
efficacy, which is essential if we are to avoid a new generation
of TB vaccines being subject to the same pitfall as BCG.
Differences in the humoral immune response observed between
BCG strains and vaccine manufacture methods may be one
contributing factor. It would also be of interest to compare
BCG-induced antibody responses between populations where
BCG varies in efficacy and determine potential associations with
NTM exposure. A study by Sebina et al. found no differences in
mycobacteria-specific antibody levels between volunteers with or
without travel history to M.tb endemic areas, but indicated that
some unvaccinated uninfected individuals possess cross-reactive
antibodies and memory B cells likely induced by exposure to
NTMs or other pathogens (44).
It has long been recognized that BCG has complex and
diverse immunomodulatory influences ranging from effects on
autoimmune disease to atopic disorders and cancer. Such off-
target effects are relevant in the context of vaccination as a
TB vaccine candidate designed to replace BCG should ideally
be non-inferior in non-specific as well as specific efficacy.
Furthermore, as novel candidates in the current pipeline include
both homologous and heterologous BCG prime-boost regimens,
understanding the mechanism of non-specific immunity opens
the possibility of boosting such responses to the host advantage.
However, study findings are often divergent, and subject to
the same confounders as those of specific responses to BCG
such as time of, or since, vaccination and additional external
influences on the immune system. While it is clear that the
effect of BCG vaccination on IgE antibody responses and
atopic disorders is beneficial in at least some populations,
heterologous humoral immune responses in other contexts
may represent a double-edged sword leading to autoimmunity
through molecular mimicry.
In conclusion, as we begin to appreciate a role for the humoral
immune response in protection from TB, further studies should
be aimed at elucidating the nature and relevance of the humoral
immune response to BCG vaccination and how this may be
harnessed to better design novel candidate vaccines for TB
and bTB.
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